Use of influenza antiviral agents by ambulatory care clinicians during the 2012-2013 influenza season

Clinical Infectious Diseases

Volumn 59, Issue 6, 2014, Pages 774-782

  Havers, Fiona ^a   Thaker, Swathi ^a   Clippard, Jessie R ^a   Jackson, Michael ^b   McLean, Huong Q ^c   Gaglani, Manjusha ^d   Monto, Arnold S ^e   Zimmerman, Richard K ^f   Jackson, Lisa ^b   Petrie, Josh G ^e   Nowalk, Mary Patricia ^f   Moehling, Krissy K ^f   Flannery, Brendan ^a   Thompson, Mark G ^a   Fry, Alicia M ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b GROUP HEALTH RESEARCH INSTITUTE   (United States)

^c MARSHFIELD CLINIC   (United States)

^d TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^e UNIVERSITY OF MICHIGAN SCHOOL OF PUBLIC HEALTH   (United States)

^f UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Ambulatory care; Antiviral treatment; Influenza; Neuraminidase inhibitors

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; OSELTAMIVIR; ZANAMIVIR; ANTIVIRUS AGENT;

ACUTE RESPIRATORY TRACT DISEASE; ADOLESCENT; ADULT; AGED; AMBULATORY CARE; ARTICLE; CHILD; DRUG UTILIZATION; DYSPNEA; FEMALE; FEVER; HIGH RISK POPULATION; HUMAN; INFANT; INFECTION COMPLICATION; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; POLYMERASE CHAIN REACTION; PRESCRIPTION; PRIORITY JOURNAL; SEASONAL INFLUENZA; SORE THROAT; WHEEZING; CLINICAL PRACTICE; CLINICAL TRIAL; HISTORY; INFLUENZA, HUMAN; MIDDLE AGED; MULTICENTER STUDY; PRESCHOOL CHILD; RISK; SEASON; STANDARDS; STATISTICS AND NUMERICAL DATA; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; AMBULATORY CARE; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; DRUG PRESCRIPTIONS; DRUG UTILIZATION; HISTORY, 21ST CENTURY; HUMANS; INFANT; INFLUENZA, HUMAN; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; RISK; SEASONS;

EID: 84907391712     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu422     Document Type: Article

References (32)

1. Muthuri SG, Venkatesan S, Myles PR, et al. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. Lancet Respir Med 2014; 2:395-404.
2. Hernan MA, Lipsitch M. Oseltamivir and risk of lower respiratory tract complications in patients with flu symptoms: a meta-analysis of eleven randomized clinical trials. Clin Infect Dis 2011; 53:277-9.
3. Lipsitch M, Hernan MA. Oseltamivir effect on antibiotic-treated lower respiratory tract complications in virologically positive randomized trial participants. Clin Infect Dis 2013; 57:1368-9.
4. Ebell MH, Call M, Shinholser J. Effectiveness of oseltamivir in adults: a meta-analysis of published and unpublished clinical trials. Fam Pract 2013; 30:125-33.
5. Torres JP, O'Ryan M, Herve B, et al. Impact of the novel influenza A (H1N1) during the 2009 autumn-winter season in a large hospital setting in Santiago, Chile. Clin Infect Dis 2010; 50:860-8.
6. Sugaya N, Shinjoh M, Mitamura K, Takahashi T. Very low pandemic influenza A (H1N1) 2009 mortality associated with early neuraminidase inhibitor treatment in Japan: analysis of 1000 hospitalized children. J Infect 2011; 63:288-94.
7. Fiore AE, Fry A, Shay D, et al. Antiviral agents for the treatment and chemoprophylaxis of influenza - recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011; 60:1-24.
8. Belongia EA, Irving SA, Waring SC, et al. Clinical characteristics and 30-day outcomes for influenza A 2009 (H1N1), 2008-2009 (H1N1), and 2007-2008 (H3N2) infections. JAMA 2010; 304:1091-8.
9. Greene SK, Shay DK, Yin R, et al. Patterns in influenza antiviralmedication use before and during the 2009 H1N1 pandemic, Vaccine Safety Datalink Project, 2000-2010. Influenza Other Respir Viruses 2012; 6:e143-51.
10. Borders-Hemphill V, Mosholder A. U.S. utilization patterns of influenza antiviral medications during the 2009 H1N1 influenza pandemic. Influenza Other Respir Viruses 2012; 6:e129-33.
11. Doshi S, Kamimoto L, Finelli L, et al. Description of antiviral treatment among adults hospitalized with influenza before and during the 2009 pandemic: United States, 2005-2009. J Infect Dis 2011; 204:1848-56.
12. Hicks LA, Chien YW, Taylor TH Jr, Haber M, Klugman KP; Active Bacterial Core Surveillance Team. Outpatient antibiotic prescribing and nonsusceptible Streptococcus pneumoniae in the United States, 1996-2003. Clin Infect Dis 2011; 53:631-9.
13. Costelloe C, Metcalfe C, Lovering A, Mant D, Hay AD. Effect of antibiotic prescribing in primary care on antimicrobial resistance in individual patients: systematic review and meta-analysis. BMJ 2010; 340:c2096.
14. Nyquist AC, Gonzales R, Steiner JF, Sande MA. Antibiotic prescribing for children with colds, upper respiratory tract infections, and bronchitis. JAMA 1998; 279:875-7.
15. Shapiro DJ, Hicks LA, Pavia AT, Hersh AL. Antibiotic prescribing for adults in ambulatory care in the USA, 2007-09. J Antimicrob Chemother 2014; 69:234-40.
16. Steinman MA, Landefeld CS, Gonzales R. Predictors of broad-spectrum antibiotic prescribing for acute respiratory tract infections in adult primary care. JAMA 2003; 289:719-25.
17. Ohmit SE, Thompson M, Petrie JG, et al. Influenza vaccine effectiveness in the 2011-2012 season: protection against each circulating virus and the effect of prior vaccination on estimates. Clin Infect Dis 2013; 58:319-27.
18. Henkle E, Irving SA, Naleway AL, et al. Comparison of laboratory-confirmed influenza and noninfluenza acute respiratory illness in healthcare personnel during the 2010-2011 influenza season. Infect Control Hosp Epidemiol 2014; 35:538-46.
19. Jia H, Lubetkin EI. Estimating EuroQol EQ-5D scores from Population Healthy Days data. Med Decis Making 2008; 28:491-9.
20. Cheung K, Oemar M, Oppe M, Rabin R. User guide: basic information on how to use EQ-5D. Rotterdam, Netherlands: EuroQol Group, 2009.
21. EuroQol Group. EuroQol - a new facility for the measurement of health-related quality of life. Health Policy 1990; 16:199-208.
22. Centers for Disease Control and Prevention. Updated interim recommendations for the use of antiviral medications in the treatment and prevention of influenza for the 2009-2010 season. Atlanta, GA: CDC, 2009.
23. Heinonen S, Silvennoinen H, Lehtinen P, et al. Early oseltamivir treatment of influenza in children 1-3 years of age: a randomized controlled trial. Clin Infect Dis 2010; 51:887-94.
24. Centers for Disease Control and Prevention. Influenza activity - United States, 2012-13 season and composition of the 2013-14 influenza vaccine. MMWR Morb Mortal Wkly Rep 2013; 62:473-9.
25. Centers for Disease Control and Prevention. Office-related antibiotic prescribing for persons aged
26. Grijalva CG, Nuorti JP, Griffin MR. Antibiotic prescription rates for acute respiratory tract infections in US ambulatory settings. JAMA 2009; 302:758-66.
27. Roumie CL, Halasa NB, Grijalva CG, et al. Trends in antibiotic prescribing for adults in the United States - 1995 to 2002. J Gen Intern Med 2005; 20:697-702.
28. Steinman MA, Gonzales R, Linder JA, Landefeld CS. Changing use of antibiotics in community-based outpatient practice, 1991-1999. Ann Intern Med 2003; 138:525-33.
29. Vanderweil SG, Pelletier AJ, Hamedani AG, Gonzales R, Metlay JP, Camargo CA Jr. Declining antibiotic prescriptions for upper respiratory infections, 1993-2004. Acad Emerg Med 2007; 14:366-9.
30. Shehab N, Patel PR, Srinivasan A, Budnitz DS. Emergency department visits for antibiotic-associated adverse events. Clin Infect Dis 2008; 47:735-43.
31. Monto AS, Gravenstein S, Elliott M, Colopy M, Schweinle J. Clinical signs and symptoms predicting influenza infection. Arch Intern Med 2000; 160:3243-7.
32. Ohmit SE, Monto AS. Symptomatic predictors of influenza virus positivity in children during the influenza season. Clin Infect Dis 2006; 43:564-8.